Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.

AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.

Cencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.

Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.

A $1,000 investment in McKesson (MCK) made in September 2016 would be worth $4,795.36 as of September 1, 2026, representing a 379.54% gain and significantly outperforming the S&P 500's 254.05% return. The pharmaceutical distributor is benefiting from growth in specialty pharmaceuticals, oncology services, and GLP-1 medications, with FY26 revenues reaching $403.4 billion and adjusted EPS up 18% year-over-year. Analysts remain optimistic with recent earnings estimate revisions and raised fiscal 2027 guidance.

McKesson disclosed a data breach on August 25, 2026, affecting 284 million records belonging to tens of millions of patients. Compromised information includes personal identities, healthcare identifiers, medical records, prescription data, and highly sensitive health information. Ademi LLP is investigating potential data privacy claims and advising affected individuals to monitor financial accounts and consider credit protection measures.

The article recommends three healthcare dividend growth stocks for investors seeking portfolio stability during market volatility: Johnson & Johnson (a Dividend King with 64 consecutive years of dividend increases), UnitedHealth Group (rebounding after recent challenges with a 2.26% yield), and McKesson (the largest U.S. pharmaceutical distributor with steady dividend growth). Healthcare is highlighted as a defensive sector due to non-discretionary spending patterns.

Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declining sales projections for 2026 and significant debt challenges. The article recommends Eli Lilly as the better buy despite premium valuation due to its continued GLP-1 growth momentum.

The global revenue cycle management (RCM) market is projected to grow at a CAGR of 11.51% from $200.1 billion in 2026 to $663.3 billion by 2035, driven by widespread EHR adoption, shift to value-based care models, and increasing use of AI and automation. North America holds the largest market share due to its complex healthcare system and advanced technology infrastructure. Key players include 3M, Change Healthcare, Optum, and McKesson, though high implementation costs and regulatory complexity present challenges.

The global healthcare analytics market is projected to grow from USD 56 billion in 2025 to USD 390 billion by 2034, with a CAGR of ~24%. Growth is driven by widespread EHR adoption, rising chronic disease prevalence, shift toward value-based care, AI/ML integration, and government digital health initiatives. North America leads with 44.36% market share, while Asia-Pacific emerges as a major growth engine.

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.